The sharp revenue decline and cash burn are concerning, but the FDA acceptance of AVT16 and $295M backlog provide a pipeline catalyst. Monitor the AVT16 review timeline (6 months) and Q2 revenue recovery as production normalizes. The 2026 guidance implies a significant H2 ramp — watch for execution risk.
Price Chart
Executive Summary
Alvotech filed its Q1 2026 6-K, reporting total revenues of $105.9M (down 20% YoY from $132.8M) and a profit of $1.0M (down from $109.7M), driven by a production slowdown and lower product revenue. The filing also announces FDA acceptance of the BLA for AVT16 (biosimilar to Entyvio) and provides 2026 guidance of $650-700M revenue and $180-220M adjusted EBITDA. The sharp revenue decline and cash burn (-$107.6M) are partially offset by pipeline progress and a $294.6M backlog of remaining performance obligations.
Key Facts
- Total revenues fell to $105.9M in Q1 2026 from $132.8M in Q1 2025, a 20% decline.
- Product and service revenue dropped to $51.2M from $109.9M, while development/service revenue rose to $54.7M from $0.
- Net profit was $1.0M vs $109.7M in the prior year period; basic EPS was $0.00 vs $0.39.
- Cash and cash equivalents fell to $63.8M from $172.4M at year-end 2025, a $108.6M decline.
- Net cash used in operating activities was $60.4M vs $12.5M provided in Q1 2025.
- FDA accepted BLA for AVT16 (proposed interchangeable biosimilar to Entyvio) for review; expected review up to 6 months.
- Management guided 2026 total revenue of $650-700M and adjusted EBITDA of $180-220M.
- Remaining performance obligations under out-license contracts estimated at $294.6M, expected to be recognized over next 5 years.
- Total debt stood at $1.31B, with weighted-average interest rate of 9.42%.
- Accumulated deficit was $2.41B; shareholders' equity was negative $282.3M.
Financial Impact
Revenue declined ~$27M YoY; cash burn of ~$108M in Q1; $1.3B debt load with 9.4% avg interest; $295M backlog provides future revenue visibility.
Risk Factors
- Revenue decline of 20% YoY driven by production slowdown; recovery uncertain.
- Cash burn of $108M in Q1; only $63.8M cash left against $1.3B debt.
- Negative equity of $282M and going concern reliance on future financing.
- FDA Form 483 observations at Reykjavik facility could delay approvals.
- High debt load ($1.31B) with 9.4% interest rate strains cash flow.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003974 |
| Exhibit: exh_992.htm | 0001171843-26-003974 |
| Exhibit: exh_991.htm | 0001171843-26-003974 |
| Document: f6k_060826.htm | 0001171843-26-003974 |
| Document: 0001171843-26-003974-index-headers.html | 0001171843-26-003974 |
| Document: 0001171843-26-003974-index.html | 0001171843-26-003974 |
| Document: 0001171843-26-003974.txt | 0001171843-26-003974 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 8, 2026 20w ago | 6-K | $0.2965 $0.3200 | ▲ +7.93% | ▲ +3.03% | — |
Jun 4, 2026 20w ago | 6-K | $0.3301 $0.4900 | ▲ +48.44% | ▲ +46.56% | — |
May 11, 2026 24w ago | 6-K | $0.3301 | awaiting T+60 | — | — |
May 4, 2026 25w ago | 6-K | $0.3301 | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers